Next-Generation Long-Read Sequencing for Multi-Dimensional Molecular Profiling
Unlocking the full spectrum of molecular information — from DNA sequence to RNA quantification, structural variation, and epigenetic modification, all in a single platform.
Sequencing Principle
A biological nanopore protein is fixed in an insulating polymer membrane. As nucleic acid single strands pass through the pore, characteristic current changes are recorded — enabling direct sequencing.
Revolutionary new nanopore protein combined with motor protein for controlled strand speed. Dramatically reduces analytical redundancy and improves clinical accessibility.
Sequence and analyze in real time — no need to wait for the entire run to complete. Get actionable insights as soon as sufficient data coverage is achieved.
DNA/RNA
Nanopore
Current Signal
Base Calling
Direct electronic sensing — no optics, no cameras, no chemistry enzymes required beyond the motor protein
Key Metrics
Raw Accuracy (Q20)
IP Achievements
Product Deliveries
R&D → Production
Core Advantages
MB-level read lengths span entire genomic regions that short-read technologies cannot resolve. Enables confident detection of complex structural variations and full-length transcripts.
No reverse transcription and no PCR amplification needed. Eliminate amplification bias entirely. Directly detect and quantify RNA while preserving the most native biological information.
No bisulfite conversion needed — avoiding DNA damage and enabling simultaneous genome sequence + methylation profiling at single-molecule resolution.
Innovative chip cleaning kit design enables flow cell reuse across multiple runs, significantly reducing the per-sample sequencing cost and making high-quality sequencing economically accessible.
Product Portfolio
Portable / POCT
Compact and portable, designed for field deployment and point-of-care settings. Perfect for rapid molecular profiling in non-traditional laboratory environments.
Six-Channel Clinical Routine
Six independent channels enable simultaneous processing of multiple samples or conditions. Designed for daily clinical routine and clinical trial laboratory use.
High-Throughput Central Lab
High-throughput platform delivering up to 800GB of sequencing data per run. Designed for centralized laboratory deep sequencing and comprehensive molecular profiling.
Multi-Dimensional Biomarkers
Unlike single-technology platforms, the Nanopore platform simultaneously captures four independent molecular dimensions — enabling comprehensive characterization impossible with any single other technology.
DNA → RNA
Direct RNA sequencing without reverse transcription or PCR amplification eliminates amplification bias entirely.
Full-length transcript detection: Resolve complete RNA isoforms and accurately distinguish between splice variants (isoforms).
Key Applications:
Large-Scale Genomic Rearrangements
Long reads (MB-level) span complex rearrangements, large deletions/insertions, and inversions that short reads miss entirely.
Critical finding: Short-read NGS sensitivity for detecting SVs >50bp is only 30–50%; Nanopore long reads can achieve 90%+.
Key Applications:
Direct 5mC Detection — No Bisulfite
Direct detection of 5mC methylation without bisulfite conversion — avoiding DNA damage and simultaneously obtaining genome sequence + methylation map at single-molecule resolution.
Bisulfite-free advantage: Bisulfite treatment degrades 84–96% of DNA; Nanopore avoids this entirely, enabling analysis of low-input and degraded clinical samples.
Key Applications:
Epitranscriptomics — m6A, m5C and Beyond
Direct detection of m6A, m5C, and other RNA modifications without chemical conversion — preserving the most native biological information and providing entirely new diagnostic dimensions.
Novel CDx frontier: RNA modifications represent the next frontier of companion diagnostics — enabling characterization beyond simple nucleotide sequence to functional RNA state.
Key Applications:
Clinical Applications
| Cancer Type | Nanopore Extended Capability | Corresponding Targeted Therapies |
|---|---|---|
| Non-Small Cell Lung Cancer | Full-length ALK/ROS1/RET fusion transcripts, methylation subtyping, resistance mechanism characterization (T790M, C797S) | Osimertinib, Alectinib, Brigatinib, Lorlatinib, Pralsetinib, Selpercatinib, etc. |
| Colorectal Cancer | MSI status, HER2 amplification, NTRK fusion, methylation-based classification, KRAS/RAF variant phasing | Cetuximab, Panitumumab, Sotorasib, Encorafenib+Cetuximab, Larotrectinib, etc. |
| Thyroid Cancer | TERT promoter methylation, full-length fusion transcript validation, RAS variant phasing | Selpercatinib, Pralsetinib, Dabrafenib+Trametinib, etc. |
| Pancreatic Cancer | BRCA1/2 large fragment rearrangement, SMAD4 deletion, structural variation, methylation profiling | Olaparib (maintenance), Erlotinib, Nab-paclitaxel+Gemcitabine, etc. |
| Breast Cancer (Developing) | HER2 amplification validation, BRCA1/2 structural variation, PIK3CA mutation phasing, immune gene expression | Trastuzumab, Pertuzumab, Olaparib, Alpelisib, etc. |
| Hematologic Malignancies (Developing) | Chromosomal translocation full-length validation, T-cell receptor repertoire, methylation classification | Imatinib, Dasatinib, Midostaurin, Ivosidenib, Venetoclax, etc. |
Technical Specifications
| Parameter | Specification |
|---|---|
| Read Length | MB-level ultra-long reads |
| Raw Accuracy | ≥99% (Q20, C2.0 chemistry) |
| Analysis Mode | Real-time — sequence and analyze as you go |
| Direct RNA Sequencing | Supported — no RT or PCR required |
| Direct 5mC Methylation | Supported — no bisulfite conversion |
| Structural Variation | Excellent — >90% sensitivity for >50bp SVs |
| Methylation Detection | Direct, single-molecule resolution, no bisulfite |
| Flow Cell Reusability | Supported via cleaning kit protocol |
| Regulatory Status | National Key R&D Program Support |
Dual-Platform Synergy
Rapid, automated testing for known mutations. 3–4 hours enables same-day clinical decisions.
Long-read multi-omics: RNA, SV, methylation, modification. Full molecular characterization.
The dual-platform approach covers the entire CDx spectrum: PCR POCT provides rapid screening for known biomarkers to accelerate enrollment, while Nanopore delivers multi-dimensional molecular profiling including RNA quantification, structural variation, and epigenetic analysis. Together, they transform CDx from sequential single-gene tests into a comprehensive molecular characterization workflow.
Learn About PCR POCT Platform →Contact us to discuss collaboration opportunities, technical profiles, or research partnership.
Email: inquiry@novobaybio.com